#### FGAI4H-J-039-A01

E-meeting, 30 September – 2 October 2020

**Source:** Editors

**Title:** Updated DEL2.2 – Att.1: Presentation

**Purpose:** Discussion

Contact: Christian Johner E-mail: christian.johner@johner-institut.de

Pradeep Balachandran <a href="mailto:pbn.tvm@gmail.com">pbn.tvm@gmail.com</a>

**Abstract:** This PPT summarizes the content of J-039 with the updated text of DEL2.2

"Good practices for health applications of machine learning: Considerations for manufacturers and regulators", for presentation and discussion during the

e-meeting, 30 September – 2 October 2020.

# AI4H Guideline

A Project Update

By Pradeep Balachandran, Luis Oala, Sven Piechottka, and Christian Johner

### Target

#### Contribute to medical devices with highest possible

- Safety
- Performance
- Clinical benefit

#### Promote common understanding of Al Best Practices

- Manufacturers
- Notified Bodies
- Authorities

#### Accelerate Time to Market


- Development
- Verification and Validation
- Approval



## Target Audience



## Structure, Example




#### 5.3.1 Data collection

**Table 11: Data collection requirements** 

| 2 References   | REQ. ID   | Requirement(s)   | Checklist item(s)  | Checklist examples and   | Priority        | Standards /   |
|--|-----------|--|--|--|-----------------|---|
| ▼ 3 Terms, definitions and   |           |  |  | comments   |                 | Regulations   |
| 3.1 Terms  |           |  |  |  |                 | applicable  |
| 3.2 Abbreviations and acronyms  ▼ 4 General requirements  4.1 Process requirements  4.2 Competency requirements  ▼ 5 Pre-market requirements  ▼ 5.1 Intended use and  5.1.1 Intended medical | DAT_CL-1  | The manufacturer should specify the number of required data sets.                              | <ul> <li>There is a specification of number of data sets.</li> <li>There is a rationale for this number.</li> </ul>  | The division into training, test and validation data sets is scope of chapter 5.4.1.   |                 | ISO 13485 clause 7.3.7 FDA proposed regulatory framework for modifications to AI/ML based SaMD: "statistical analysis |
| 5.1.2 Intended users and   |           |  |  |  |                 |   |
| 5.1.3 Stakeholder  |           |  |  |  |                 | plan"   |
| 5.1.4 Risk management and  | DATE OF A | TTI C 4 1 11   |  | TD 1 : 1: 1 : / 1 :  | D / M           | _   |
| ▼ 5.2 Product and software   |           | The manufacturer should specify the inclusion and exclusion criteria for individual data sets. | <ul> <li>There is a specification of technical requirements.</li> <li>There is a specification of patient attributes that have to be met to include a data set.</li> </ul> | Technical inclusion / exclusion criteria may include for each attribute:  — data ranges  | Data Management | ISO 24028  XAVIER University "Building Explainability an Trust for AI in Healthcare"                                  |
| 5.2.1 Functionality and  |           |  |  |  |                 |   |
| 5.2.2 User interface   |           |  |  |  |                 |   |
| 5.2.3 Additional software  |           |  |  |  |                 |   |
| 5.2.4 Risk management  |           |  |  | <ul> <li>data type (numeric (float, integer etc.), ordinal, categorical, String / text, date / time, image / binary)</li> <li>data formats (e.g. date and number formats)</li> </ul> |                 |   |
| ▼ 5.3 Data management  |           |  |  |  |                 |   |
| 5.3.1 Data collection  |           |  |  |  |                 |   |
| 5.3.2 Data annotation  |           |  |  |  |                 |   |
| 5.3.3 Data pre-processing  |           |  |  |  |                 |   |
| 5.3.4 Documentation and  |           |  |  |  |                 |   |
| ▼ 5.4 Model development  |           |  |  |  |                 |   |
| 5.4.1 Model preparation  |           |  |  | <ul><li>unit of measure</li></ul>  |                 |   |
| 5.4.2 Model training   |           |  |  |  |                 |   |
| 5.4.3 Model evaluation   |           |  |  | <ul><li>precision of numbers</li></ul>   |                 |   |
| 5.4.4 Model documentation  |           |  |  | <ul><li>attributes values</li></ul>  |                 |   |
| ▼ 5.5 Product development  |           |  |  | 24 2   |                 |   |

### Included Regulations & Best Practices



### Additional accomplishments

- Integration of IT security aspects
- Compilation of "marketing flyer"
- Alignment with guideline by German Notified Bodies (NBs) (this NB guideline builds on the roots of our guideline)



| die Anwendung der Verfahren des maschinellen Lernens ergeben?               | 4.4.                |
|---|---------------------|
| ➤ Hat der Hersteller die Risiken analysiert, die sich ergeben, wenn andere  | • ISO 14971, 5.     |
| als die spezifizierten Nutzer das Produkt nutzen?                           |                     |
| > Hat der Hersteller die Risiken analysiert, die sich durch die Nutzung in  | • 2017/745/EU       |
| einer anderen als der spezifizierten Nutzungsumgebung ergeben?              | Anhang 1 Nr. 14.2.  |
|   | Buchstabe d         |
|   | • ISO 14971, 5.     |
|   | • IEC 82304, 4.1. c |
| ➤ Hat der Hersteller die Risiken analysiert, die sich ergeben durch Inputs, | • ISO 14971, 5.     |
| die nicht den spezifizierten Formaten genügen und/oder nicht                | • IEC 82304, 4.1. c |
| entsprechend den spezifizierten Voraussetzungen generiert wurden?           |                     |